Telefonaktiebolaget LM Ericsson (publ) (ERIC)
Ericsson is a world-leading supplier in the fast-growing and dynamic telecommunications and data communications industry, offering advanced communications solutions for mobile and fixed networks, as well as consumer products. The company is a total solutions supplier for all customer segments: network operators and service providers, enterprises and consumers. The company has the world’s largest customer base in the telecommunications field.
Telefonaktiebolaget LM Ericsson (publ) (ERIC)‘s Financial Overview
Telefonaktiebolaget LM Ericsson (publ) (ERIC) closed its trading session at $6.36. The company has 1 year Price Target of $5.94. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 4.61 Million shares yesterday. The firm shows the market capitalization of $21.72 Billion.
Telefonaktiebolaget LM Ericsson (publ) (ERIC) reported its last quarterly earnings on 12/30/2017 where the firm reported its Actual EPS of $0.05/share. The difference between the actual and expected EPS is $0.02 a share with a surprise factor of 66.7%.
The firm is trading with SMA20 of -4.38 Percent, SMA50 of SMA50 Percent and SMA200 of -1.16 percent. Telefonaktiebolaget LM Ericsson (publ) has P/S value of 0.89 while its P/B value stands at 1.73. Similarly, the company has Return on Assets of -12.9 percent, Return on Equity of -30.4 percent and Return on Investment of -25.5 Percent. The company shows Gross Margin and Operating Margin of 25.1 percent and -18.9 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 3.2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 26 analysts offering 12-month price forecasts for Telefonaktiebolaget LM Ericsson have a median target of 6.50, with a high estimate of 8.86 and a low estimate of 3.00. The median estimate represents a +2.21% increase from the last price of 6.36.
CorMedix, Inc. (CRMD)
CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company’s therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin®. CorMedix Inc. is based in Summit, New Jersey.
CorMedix, Inc. (CRMD)’s Financial Outlook
The 1 analysts offering 12-month price forecasts for CorMedix Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate represents a +2,105.07% increase from the last price of 0.18.
According to Zacks Investment Research, CorMedix, Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock declined-3.51% and closed its last trading session at $0.18. The company has the market capitalization of $12.81 Million. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 4.61 Million shares. The company has a total of 70.62 Million shares outstanding.
The company has YTD performance of -63.86 percent. Beta for CorMedix, Inc. stands at 0.85 while its ATR (average true range) is 0.04. The company has Weekly Volatility of 13.40%% and Monthly Volatility of 11.67%.
CorMedix, Inc. has distance from 20-day Simple Moving Average (SMA20) of -33.68%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of -60.96%.